Back

When should we add PCSK-9 inhibitors?

27 August 2018 (09:15 - 09:37)
Organised by:
Congress Presentation Part of: Lipid-lowering therapy: how to tailor treatment to your patient Risk Factors and Prevention ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Stephen Nicholls

Monash University, Melbourne (Australia)

3 More presentations in this session

Presentation thumbnail
Treatment intensity in primary and secondary prevention? The role of precision medicine.
Professor J. Deanfield (London, GB)
Slides Video
Presentation thumbnail
Should we address other lipid/lipoproteins besides LDL-C?
Professor R. Frikke-Schmidt (Copenhagen, DK)
Slides Video
Presentation thumbnail
Is there a place for anti-inflammatory medication in clinical practice?
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy: how to tailor treatment to your patient

The Event

Event poster

ESC Congress 2018

27 August 2018 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Coronary risk reduction intervention for siblings and offspring of patients with premature coronary heart disease: the criso project.
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Webinar
Risk assessment and lipid management in primary prevention

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources